The reinvention of Baxter goes on. The company that in the early 2000s was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in 2025 after spinning off renal care in 2024.
MTI100 - Into 2025: Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’
Things Can Only Get Better? Medtechs Refocus On Core Drivers, Express Nuanced Views About AI
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
More from Company Rankings
• By
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
• By
Top 100 publicly listed medtech companies ranked by global revenues, and listings for the top cardiology, orthopedic, IVD and imaging performers based on 2023 or 2023-24 revenues, are now available from Medtech Insight.
More from Medtech Insight
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
Exer Labs Inc.’s website marketed its AI-based Exer Scan app to “screen and treat Parkinson’s, TB, Cerebral Palsy and more.” But those claims went well beyond what was allowed under the product’s 510(k) clearance, US regulators say.
• By
Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.